Combination therapy for visceral leishmaniasis

Summary Combination therapy for the treatment of visceral leishmaniasis has increasingly been advocated as a way to increase treatment efficacy and tolerance, reduce treatment duration and cost, and limit the emergence of drug resistance. We reviewed the evidence and potential for combination therap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet infectious diseases 2010-03, Vol.10 (3), p.184-194
Hauptverfasser:	van Griensven, Johan, MD, Balasegaram, Manica, MD, Meheus, Filip, MSc, Alvar, Jorge, MD, Lynen, Lutgarde, MD, Boelaert, Marleen, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Amphotericin B - therapeutic use Antiprotozoal Agents - therapeutic use Asia - epidemiology Biological and medical sciences Brazil - epidemiology Cost-Benefit Analysis Drug resistance Drug Therapy, Combination - economics Emergency medical services Europe - epidemiology Human protozoal diseases Humans Infectious Disease Infectious diseases Leishmaniasis, Visceral - drug therapy Leishmaniasis, Visceral - epidemiology Leshmaniasis Medical sciences Meglumine - therapeutic use Organometallic Compounds - therapeutic use Parasitic diseases Phosphorylcholine - analogs & derivatives Phosphorylcholine - therapeutic use Protozoal diseases Public health Safety South Africa - epidemiology Vector-borne diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!